EIF2A and lung carcinoma: Mutant KRAS causes a persistent activation of the PERK/p-eIF2α pathway (Supplementary Fig. 6), which accounts for the higher susceptibility of mutant than WT KRAS lung cancer cells to ISR inhibition (Fig. 6a, b; Supplementary Fig. 7).